Vantia Limited

Vantia Limited

Nocturia drug development

Vantia Therapeutics is a drug development company.  Founded on Ferring Research's 21 year experience in small molecule discovery & early development, Vantia was formed in late 2007 and acquired a series of drug assets and people from Ferring in March 2008.  The Company is based on Southampton University's Science Park at Chilworth in the UK.  Vantia's lead assets are VT483, a vasopressin agonist in Phase II clinical trials for the treatment of nocturia and VT913, a vasopressin antagonist for the treatment of dysmennhorrea, also in Phase II studies.

Contact Name
Mr. Andy Crockett

Company Position
Chief Executive Officer

Contact Address
Epsilon House
Southampton Science Park
Enterprise Road
SO16 7NS